A study by Joan XXIII Hospital in Tarragona has confirmed that the monoclonal antibody nirsevimab reduces hospital admissions for bronchiolitis caused by respiratory syncytial virus (RSV) by 80% among children under 6 months of age. The research, conducted in collaboration with the Universitat Rovira i Vi…
A study by Joan XXIII Hospital in Tarragona has confirmed that the monoclonal antibody nirsevimab reduces hospital admissions for bronchiolitis caused by respiratory syncytial virus (RSV) by 80% among children under 6 months of age.
The research, conducted in collaboration with the Universitat Rovira i Virgili (URV) in Tarragona and published in The Pediatric Infectious Disease Journal, also found a 55% reduction in admissions to the pediatric intensive care unit (PICU), the hospital said in a statement on Wednesday.
The study analyzed 1,384 hospitalizations for acute lower respiratory tract infections in children under 5 years of age recorded over six RSV epidemic seasons between 2018 and 2025. The results show that, following the introduction of nirsevimab, the hospitalization rate for RSV fell from 5.04 to 2.51 cases per 1,000 children under 5, while pediatric intensive care admissions for respiratory infections decreased from 2.9 to 1.3 cases per 1,000 children.
The team did not detect an increase in hospital admissions caused by other respiratory viruses, nor an increase in disease severity or in the number of hospitalizations among children who received nirsevimab during the first season and were exposed to the virus the following year.
ConSalud content is produced by journalists specializing in health and endorsed by a committee of leading experts. Nevertheless, we recommend that readers consult a healthcare professional regarding any health-related questions or concerns.
